Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

Ophthalmic disease

INDICATION: Diabetic macular edema (DME)

Patient sample and mouse studies suggest inhibiting MMP9 could help treat DME. Levels of

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE